• Enveric Biosciences’ third-quarter 2026 net loss attributable to stockholders narrowed 26% year-over-year to $2.5 million.
• Cash on hand totaled $5.6 million at September 30, 2026.
• Final IND-enabling activities for EB-003 advanced ahead of a planned IND submission and first-in-human Phase 1 trial.
• A preclinical qEEG study demonstrated brain penetration and a brain activity profile distinct from DMT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261113748951) on November 13, 2026, and is solely responsible for the information contained therein.